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ABSTRACT 
 
 
 Endovascular therapy involves the placement of an implantable filler coil directly into 
an aneurysm sac to occlude the space and promote healing of the damaged vessel wall. 
Implantable devices must be tested to assess and address all potential risks that they may pose. 
Shape memory polymer (SMP) foams have been placed over nitinol coils as an endovascular 
treatment option for cerebral aneurysms. These foams have large potential for use in aneurysm 
embolization, but it is unknown whether they will generate harmful particulate matter upon 
implantation into the body. Particulates could be the result of damaged or weakened foam 
struts that are prone to fracture upon agitation or external forces. Currently, there are no 
existing protocols for the quantification of particulate matter in SMP embolic devices. The 
focus of this work was to investigate particulate levels in SMP foams and foam devices.  
 Protocols were developed to quantify particulate formation in a foam cleaning process, 
two reticulation processes, and device delivery. Furthermore, visual characterization and 
cytocompatibility testing was performed on SMP foam particulates. Results from the studies 
demonstrated that the foams and foam-based devices generate particulate levels that are in 
compliance with limits stated by the most relevant standard. When concentrated particulate 
treatments were administered to fibroblasts, they exhibited high cell viability (100%). These 
results provide further validation of the use of SMP materials in a neurovascular embolization 
device. 
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AAMI  Association for Advancement of Medical Instrumentation 
Al2O3  Aluminum oxide 
CaCl2  Calcium chloride 
CF4  Tetrafluoromethane 
DI  Deionized 
DMEM Dulbecco’s modified eagle medium 
FDA  Food and Drug Administration 
FOC  Foam-over-coil 
HDI  hexamethylene diisocyanate 
HPED  N,N,N’,N’-tetrakis(2-hydroxypropyl) ethylenediamine 
IPA  Isopropyl alcohol 
LO  Light obscuration 
MRA  Magnetic Resonance Angiography 
MTS  Insight Material Tester 
NBCS  Newborn calf serum 
NED  Neurovascular embolization device 
NR  Neutral red 
O2  Oxygen 
OD540  Optical density at 540 nm 
OH  Hydroxyl 
P/S  Penicillin/streptomycin 
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RO  Reverse osmosis 
SAH  Subarachnoid hemorrhage 
SD  Standard deviation 
SEM  Scanning electron microscopy 
SMP  Shape memory polymer 
SiO2  Silicon dioxide 
TEA  triethanolamine 
Tg  Glass transition temperature 
TIR  Technical information report 
Tm  Melt transition temperature 
TMHDI trimethyl-1,6-hexamethylene diisocyanate 
Ttrans  Transition temperature 
USP  United States Pharmacopeia  
UV  Ultraviolet 
Vol%  Volume percentage 
W  Tungsten 
Wt%  Weight percentage 
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1CHAPTER I 
INTRODUCTION 
1.1. Shape memory polymer (SMP) foam 
SMPs are “smart” materials capable of maintaining a secondary geometry and then 
returning to a primary geometry upon application of a thermal, chemical, or optical stimulus 
(Figure 1.1)1,2. The majority of SMPs exhibit thermally activated behavior3. Thermal SMPs 
form their primary shape at a temperature greater than their transition temperature (Ttrans). That 
primary shape is fixed via cooling and/or cross-linking. The secondary shape is set via 
deformation of the polymer while it is in its rubbery state at a temperature above Ttrans, and 
stabilized by cooling back to its glassy state below Ttrans.  Upon supplying thermal energy to 
the SMP (heat above Ttrans), there is sufficient entropic potential to drive shape recovery to the 
primary shape1. SMPs networks are made up of net-points and switching segments; the net 
points determine the permanent shape, and the switching segments absorb stress and permit 
deformation once heated above Ttrans
1. SMPs that are predominantly crystalline have a Ttrans 
equal to their melt transition temperature (Tm), and SMPs that are predominantly amorphous 
have a Ttrans equal to their glass transition temperature (Tg)
1. 
 Figure 1.1: Mechanism by which a SMP foam is compressed into a secondary geometry and 
returned back to its primary geometry. 
Specifically, the SMPs used here are polyurethane SMP foams. Polyurethane SMP 
foams exhibit a large Tg range (-100° C to +80° C), ultra-low densities, high porosity, X-ray 
visibility, capability for catheter delivery, low processing costs, and thermal stability4-8. The 
foams demonstrated exceptional biocompatibility, a reduced inflammatory response, the 
capability for interconnected thrombus formation, and aneurysm healing in an in vivo study in 
a porcine aneurysm model9-11.  
1.2. Neurovascular embolization for prevention of cranial aneurysms 
SMP foams are being considered as embolization materials for a number of biomedical 
applications. Each application has its own set of requirements regarding foam porosity, optimal 
foam volume, actuation time, and mechanical properties. These SMP foams exhibit low 
densities, highly tunable thermal and mechanical properties12,13, high volume recovery14, easy 
processability4, and exceptional biocompatibility9,10 making them ideal candidates for 
neurovascular embolization devices (NEDs). 
An aneurysm is a localized abnormal dilation of a blood vessel, resulting from a 
weakened or damaged vascular wall, often a side effect of atherosclerosed vascular tissue15,16. 
2
3 
Aneurysms may be congenital or acquired and occur at damage sites on vessel walls17. Typical 
locations include the aorta, peripheral vasculature, and the mesenteric (intestinal), splenic, and 
cerebral arteries18. They can be fusiform, false, or saccular aneurysms17. This work focuses on 
cerebral saccular aneurysms, spherical outpouchings ranging from 2 to 50 mm in diameter 
(average diameter = 8 mm) involving only a portion of the vessel wall17. In a Japanese study 
magnetic resonance angiography (MRA) was performed on 8,500 healthy, asymptomatic 
individuals; 3.2% of patients contain at least one unruptured saccular aneurysm in the cranial 
region19. The majority of intracranial saccular aneurysms develop at the apex of the 
subarachnoid arterial bifurcations20. If an aneurysm bursts, it results in subarachnoid 
hemorrhage (SAH), which affects as many as 30,000 Americans each year15,16. SAH causes a 
reduction in cerebral blood flow coupled with reduced cerebral autoregulation that leads to 
acute ischemia or stroke. Stroke causes an increase in intracranial blood pressure, decreased 
blood perfusion and acute vasoconstriction16, all of which pose a significant risk of decreasing 
the patient’s mental health, permanently damaging the brain, or even death. Patient mortality 
following SAH is as high as 50%, and there is substantial morbidity among survivors16. 
Currently, the primary treatment modalities for aneurysms to prevent SAH are surgical 
clipping and filling with endovascular coils (Figure 1.2A-B). 
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Figure 1.2: A saccular aneurysm (A) surgically treated with an aneurysm clip, and (B) treated 
with endovascular coil embolization therapy. 
 
Aneurysm clipping requires a high risk, invasive surgery to implant a clip that prevents 
blood from flowing into the aneurysm sac21. Aneurysm location is often a limiting factor in 
these procedures22. Endovascular coiling is a minimally-invasive alternative that aims to fill 
the aneurysm sac with material to minimize blood flow, induce thrombosis, and promote 
endothelialization of the aneurysm neck22-25. Coiling allows for greater access to tortuous 
cerebral vasculature and reduces in-hospital mortality26. In 1991, soft platinum coils were 
developed for use as filling material. The procedure involves the delivery of coils through a 
microcatheter directly into the aneurysm sac with the help of fluoroscopy imaging27. Despite 
some success in small aneurysms (< 4 mm neck diameter), platinum coils are limited by 
chronic inflammation28, low volume occlusion (23-37%)29,30, and recanalization of the 
aneurysm sac24,31,32. Later, polymer coated coils were developed to address some of these 
issues. Hydrogel coatings on platinum coils resulted in higher volume occlusion (45-85%) but 
recurrence is still an issue in aneurysms with a neck greater than 8 mm33-35. Bioactive or 
biodegradable polymer coated coils showed promising results initially but exhibited 
recanalization of the aneurysm sac as the polymer was absorbed by the body36.  
A B 
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Polyurethane SMP foams have been incorporated into an NED that is well suited for 
adoption by clinicians in the field because of its similarity to existing devices. The implant 
portion of the device contains an SMP foam secured onto a platinum wound nickel-titanium 
(nitinol) backbone wire10. The implant is laser welded and epoxied to a pusher wire that enables 
navigation through the length of the microcatheter and to the aneurysm site. Device features 
include X-ray visibility, passive actuation at body temperature (37°C), the ability for catheter 
delivery, and an electrolytic detachment mechanism10.  
1.3. Particulate matter in SMP foams 
A particulate is defined by the United States Pharmacopeia (USP) as “mobile 
undissolved particles, other than gas bubbles, unintentionally present” and can be generated by 
manufacturing processes or by the breakdown of device components37,38. For implantable 
medical devices, the FDA requires evaluation of the particulates generated by the material, 
manufacturing processes, and the final assembled device39,40. Particulates generated by an 
implanted device serve as potential emboli for downstream microvasculature41,42; un-intended 
embolization of brain microvasculature has very serious health implications that make 
particulate characterization a high priority for device evaluators40,41.   
Thus, the total size, geometry, and quantity of particulates is an indication of embolic 
risk posed by the device38. It is unknown whether the SMP foams and foam-based devices 
generate harmful levels of particulates and there is no existing protocol to quantify or 
characterize particulate matter in these materials. There are a number of processing steps 
between synthesis and implantation that could be potential sources of particulate matter. In 
polyurethane SMP foams, there is a potential for micro-fracture of the struts in the foam matrix, 
resulting in particulate generation during device fabrication, processing, and delivery5.  
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Foam fabrication was carried out using a three step process. First, an isocyanate premix 
was prepared and allowed to cure for 48 hours. Then, a hydroxyl premix was made by mixing 
surfactants, catalysts, and hydroxyl groups. Lastly, the isocyanate and hydroxyl premixes were 
combined with a physical blowing agent and left to cure for at least a week14. After foam 
fabrication, the foam is cleaned through a series of isopropyl alcohol (IPA) and reverse osmosis 
(RO) water sonications and tumble cycles, mechanically reticulated using a floating array of 
pins, cut to its desired shape using a biopsy punch, and radially compressed or “crimped” down 
to its secondary geometry. All of these processes are potential sources for particulates that 
could pose a threat upon implantation into the brain.  
1.4. Techniques for quantification of particulate matter 
Currently, there are two primary modes of particulate quantification: light obscuration 
(LO) and microscopy37. Light obscuration is the industrially favored technique because it 
allows for automated particulate quantification at a rapid and repeatable rate44.  Microscopy 
evaluation involves manually counting particulates using a light microscope and a calibrated 
micrometer44. This work focuses on the utilization of LO to quantify particulates generated by 
polyurethane SMP foams and foam devices in order to effectively evaluate the embolic risk 
posed by these SMP embolization devices.  
1.4.1. Light obscuration 
 Particulate quantification and sizing using LO is performed with a particle counter 
device. The particle counter consists of an optical sensor and specifically programmed 
counting electronics45. The sensor contains a 780 nm infrared laser diode that converts light 
energy into electrical voltage outputs. As a sample solution is flowing through the sensor, it 
disrupts a portion of the light and produces an electrical pulse proportional to its size; pulse 
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amplitude corresponds to particle size as shown in Figure 1.345.  The device groups the 
particles into size bins and provides the quantity of particles in a given sample solution for 
each size bin.  
 
 
Figure 1.3: Schematic of light obscuration (LO) flow cell on particle counter device. 
 
  Sample preparation is done according to the type of sample being analyzed. In general, 
it is based upon a protocol outlined in USP 788, a guidance document for particulate analysis 
of parenteral injections. The protocol outlines acceptable thresholds for “particle free” water 
that can be used during testing, and provides a method for sample agitation. LO particle 
counters are limited in analysis of certain sample types. Organic particles cannot be quantified 
with accurate resolution because their index of refraction is close to that of water, causing them 
to reflect more light and be recorded in a size range several microns below their actual size45. 
To address this discrepancy, size bins are used instead of exact sizes. Additionally, highly 
viscous solutions are generally not suitable for this method. 
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1.4.2. Microscopy 
 Particulate analysis via microscopy is performed manually on a binocular microscope. 
Sample solutions are passed through a filter assembly and examined on a membrane filter. 
Once the particulates have been isolated by the filter, they are manually sized and quantified 
by the operator with an ocular micrometer. This method is limited by the time needed to 
perform each count and the operator’s ability to accurately and consistently group the particles 
into the appropriate size ranges. It is not a feasible evaluation approach for a large scale 
manufacturer that needs to evaluate large numbers of samples. However, the method is 
compatible with highly viscous solutions that are not suitable for use with light obscuration 
methods. 
1.5. Summary of thesis 
 Determination of the size and number of particulates generated by polyurethane SMP 
foams is required in their development as embolic materials in biomedical applications. The 
goal of this thesis is to develop protocols for measuring and characterizing particulate matter 
in SMP foams and SMP foam-based devices.  
 Chapter II discusses the approach to quantify particulate matter after cleaning and 
reticulation processes as well as testing the cytocompatibility of uncleaned, nanoparticle-
loaded, polyurethane SMP foams using light obscuration. Particulate levels from cleaned 
foams were compared to uncleaned foams to assess the efficacy of the current cleaning process. 
Two reticulation processes are compared and evaluated on the basis of particle generation, and 
concentrated particulate solutions were taken from representative foam samples and 
administered to fibroblasts to assess cytocompatibility of particulates. The methods for 
particulate analysis and cytocompatibility testing are described, and the results are presented. 
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Visual characterization of particulates using a scanning electron microscope (SEM) was 
performed to report on particulate geometry in addition to their size and number to fully assess 
their potential embolic risk. The method for preparation of the SEM samples and identification 
of the particulates is described and the results are discussed. 
 Chapter III discusses the analysis of the particulates generated by foam-based devices 
delivered into a straight tube and tortuous model. Particulate analysis was performed on SMP 
foam devices during delivery into two flow loops of increasing tortuosity. The flow systems 
were developed to simulate delivery into a blood vessel at physiologic temperatures and 
tortuosity.  
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CHAPTER II 
PARTICULATE ANALYSIS OF VARIOUS PROCESSING STEPS FOR SHAPE 
MEMORY POLYMER FOAMS FOR ANEURYSM OCCLUSION* 
 
2.1  Introduction 
When evaluating particulate generation of a material intended for implantation, each 
step in the manufacturing and preparation process must be considered and examined as a 
potential source for particulates41. A technical information report (TIR) from the Association 
for the Advancement of Medical Instrumentation (AAMI) advises testing for particulates 
generated during manufacturing, packaging, acute application, sterilization, and degradation39. 
The FDA has yet to define specific tests detailing acceptable particulate limits for medical 
devices, but they strongly recommend measuring the size and quantity of particulates that a 
device may generate as an indication of the embolic risk that the device will pose38,41. The U.S. 
Pharmacopeial Convention’s chapter 788, “Particulate Matter in Injections” is commonly 
referenced when evaluating particulates37. It provides a protocol for counting particulates in 
solution and quantitative limits for particles >10 μm and >25 μm. However, the chapter does 
not outline a protocol for evaluating particulates generated by medical devices or provide 
acceptable thresholds for particle generation. To this end, an appropriate protocol should be 
developed to ensure that the particles will be in suspension during evaluation.  
                                                          
* Figure 2.10 in this chapter is reprinted with permission from “Modification of shape memory polymer foams 
using tungsten, aluminum oxide, and silicon dioxide nanoparticles” by S. Hasan, R. Thompson, H. Emory, A. 
Nathan, A. Weems, et al., 2016. Royal Society of Chemistry Advances, 6: 918 – 927, Copyright 2016 by Royal 
Society of Chemistry. 
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This thesis evaluates the particulate generation in SMP foams that serve as candidates 
for an NED. The foams are synthesized with varied monomer ratios and filler types, weight 
percentages (wt%), and volume percentages (vol%) to enable tailoring of the foam’s physical 
and mechanical properties. Fillers are incorporated to improve Young’s modulus and tensile 
strength of the foams6. Varying the monomer concentrations affects the hydrophobicity of the 
low density foams, and varying the weight and volume percentages of the fillers allows finer 
control of foam mechanical properties5,47. This thesis aims to provide quantitative feedback on 
the particulates generated from the foams when subject to cyclic inversion testing, cleaning, 
and two different reticulation processes. Furthermore, 3T3 fibroblast viability is assessed upon 
administration of concentrated particulate solutions. 
2.2. Materials and methods 
2.2.1. Particle counter validation 
 Validation of the particle counting system was performed by introducing a known size 
and quantity of calibrated microspheres (Count-Cal, Thermo Fisher Scientific, Waltham, MA) 
into the particle counter and ensuring that it outputted at least 75% of the particles introduced 
into the system. Microspheres 15 µm in diameter and at a concentration of 1500 particles per 
mL were used for this validation. The microspheres were suspended in 50 mL of solution; each 
test run consisted of manual inversion of the container 10 times followed by quantification of 
the particles contained in 10 mL of microsphere suspension. This sampling method allowed 4 
test runs per 50 mL sample.   
2.2.2. Materials 
N,N,N’,N’-tetrakis(2-hydroxypropyl)ethylenediamine (HPED, 99%; Sigma-Aldrich 
Inc., St. Louis, MO), triethanolamine (TEA, 98%; Sigma-Aldrich Inc., St. Louis, MO), 
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trimethyl-1,6-hexamethylene diisocyanate, 2,2,4- and 2,4,4-mixture (TMHDI; TCI America 
Inc., Portland, OR), hexamethylene diisocyanate (HDI; TCI America Inc., Portland, OR), DC 
198 (Air Products and Chemicals Inc., Allentown, PA), DC 5943 (Air Products and Chemicals 
Inc., Allentown, PA), T-131 (Air Products and Chemicals Inc., Allentown, PA), BL-22 (Air 
Products and Chemicals Inc., Allentown, PA), Enovate 245fa Blowing Agent (Honeywell 
International Inc., Houston, TX), 2-propanol 99% (IPA) (VWR, Radnor, PA) and deionized 
(DI) water (E-Pure water system, Barnstead International, Dubuque, IA) were used as received. 
Tungsten nanoparticles (W, 99.95%, 40-60 nm; US Research Nanomaterials Inc., Houston, 
TX), aluminum oxide nanoparticles (Al2O3, alpha, 99+%, 80 nm, hydrophilic; US Research 
Nanomaterials Inc., Houston, TX), and silicon dioxide nanoparticles (SiO2, 98+%, 60-70 nm, 
amorphous; US Research Nanomaterials Inc., Houston, TX) were dried under vacuum at 90° 
C for 12 hours prior to foam synthesis5.  
Penicillin/streptomycin (P/S, 1%; VWR, Radnor, PA), Dulbecco’s modified eagle 
medium (DMEM; VWR, Radnor, PA), newborn calf serum (NBCS, 10%; Sigma-Aldrich Inc., 
St. Louis, MO), fungizone (0.1%, VWR, Radnor, PA), calcium chloride (CaCl2, 0.1%; Sigma-
Aldrich Inc., St. Louis, MO), formaldehyde (0.5%; Sigma-Aldrich Inc., St. Louis, MO), acetic 
acid (1%; Sigma-Aldrich Inc., St. Louis, MO), ethanol (50%; Sigma-Aldrich Inc., St. Louis, 
MO), 3T3 fibroblasts (ATCC, Manassas, VA), and a neutral red (NR) uptake assay (TOX4, 
Sigma-Aldrich Inc., St. Louis, MO) were used as received.  
2.2.3. Foam synthesis 
Twenty different variations of SMP foams, shown in Table 1, were synthesized using 
the three-step protocol previously described by Hasan et al.5,48. Isocyanate pre-polymer were 
synthesized using appropriate molar ratios of HPED, TEA, TMHDI, and HDI, with a 35 wt%  
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hydroxyl (OH) composition. Nanoparticles were physically incorporated into the isocyanate 
pre-polymers via high shear mixing prior to foam blowing at the appropriate concentrations. 
A OH mixture was prepared with the remaining molar equivalents of HPED and TEA, along 
with catalysts, surfactants, and DI water. During foam blowing, a physical blowing agent, 
Enovate, was mixed with the isocyanate pre-polymer and the OH mixture using a speedmixer 
(SpeedMixer, FlakTek Inc., Hauschild, Germany). The resulting foams were cured in a vacuum 
oven at 90° C for 20 minutes. The SMP foam nanocomposites were cooled to room temperature 
(21 ± 1° C) followed by a 24-hour cold cure before further processing.  
SMP foams synthesized with 100% TMHDI and no fillers were used as controls. 
Eleven foams were synthesized containing either Al2O3 or SiO2 fillers with varied monomer 
ratios, as listed in Table 1. The two isocyanate monomers used were TMHDI and HDI. The 
remaining eight foams were synthesized with varying weight or volume percentages of W 
filler. Weight percentages ranged from 0.5 – 3 %, as an unfavorable decrease in mechanical 
properties is exhibited by foams with higher wt% fillers (> 3 %)5. Additionally, 3, 5, 6, and 8 
vol% W foams were assessed, due to the increased X-ray visibility exhibited by these foams48. 
Table 2.1 details the compositions of the foams synthesized. 
 
 Table 2.1: Filler type, monomer ratio, and weight or volume percentage used in foam 
syntheses. 
Foam Name Monomer Ratio Filler Particle 
Filler 
Weight % 
Filler 
Volume % 
Control 100% TMHDI --- --- --- 
50:50 1 wt% Al2O3 50% HDI 50% TMHDI Al2O3 1 --- 
20:80 1 wt% Al2O3 20% HDI 80% TMHDI Al2O3 1 --- 
0.5 wt% Al2O3 100%TMHDI Al2O3 0.5 --- 
0:100 1 wt% Al2O3 100% TMHDI Al2O3 1 --- 
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Table 2.1 Continued 
Foam Name Monomer Ratio Filler Particle 
Filler 
Weight % 
Filler 
Volume % 
2 wt% Al2O3 100% TMHDI Al2O3 2 --- 
3 wt% Al2O3 100% TMHDI Al2O3 3 --- 
4 wt% Al2O3 100% TMHDI Al2O3 4 --- 
5 wt% Al2O3 100% TMHDI Al2O3 5 --- 
0.5 wt% SiO2 100% TMHDI SiO2 0.5 --- 
1 wt% SiO2 100% TMHDI SiO2 1 --- 
2 wt% SiO2 100% TMHDI SiO2 2 --- 
0.5 wt% W 100% TMHDI W 0.5 --- 
1 wt% W 100% TMHDI W 1 --- 
2 wt% W 100% TMHDI W 2 --- 
3 wt% W 100% TMHDI W 3 --- 
3 vol% W 100% TMHDI W --- 3 
5 vol% W 100% TMHDI W --- 5 
6 vol % W 100% TMHDI W --- 6 
8 vol % W 100% TMHDI W --- 8 
 
2.2.4. Cleaning process 
Foams were subject to a cleaning process aimed towards removing any residual 
chemicals from foam synthesis, washing out any weak or damaged foam struts, and removing 
any environmental contaminants that may have been introduced during post-synthesis 
processing. The process involves two 15-minute IPA sonications, followed by a 5-minute 
tumble cycle, and four 15-minute RO water sonications. The foams were then submerged in 
RO water, and placed in a -2° C freezer for 12 hours. Lastly, the foams were placed in a freeze 
dryer (Freezone 6, Labconco Corporation, Kansas City, MO) for 12 hours at 25° C.   
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2.2.5.  Reticulation 
 Foams were subject to reticulation in order to remove or puncture the thin membranes 
between foam struts within the SMP foam matrix49. Reticulation is done to allow for better 
infiltration of blood into the foam matrix, and to improve its potential for healing once 
implanted into the aneurysm sac49,50. Mechanical and plasma reticulation methods were 
evaluated on the basis of particulate generation. The two reticulation methods were compared 
against a control foam composed of 100% TMHDI and containing no filler particles.  
2.2.5.1  Mechanical reticulation 
 
 
Figure 2.1: SEM images of (A) SMP foam prior to reticulation, (B) the mechanical reticulation 
setup, and (C) SMP foam post-reticulation. 
 
 The mechanical reticulation system includes a gravity-driven floating nitinol pin array, 
and a vertically oscillating vibratory shaker (Figure 2.1)49. Foam samples were cut to 
rectangular blocks 30 mm in height and 5 cm in length/width and then subject to the cleaning 
protocol outlined in Section 2.4. The foam blocks were held in place by custom vibratory 
mounting platform that is cyclically raised and lowered for a duration of 2.5 hours. Then, the 
foam block was turned over, re-secured, and subject to another reticulation cycle lasting 2.5 
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hours. Complete reticulation of both sides of the foam block took 5 hours. Two foam blocks 
of 100% TMHDI foam with no filler were mechanically reticulated, cut into nine 8 mm 
cylinders 30 mm (n = 10) in length using a biopsy punch (Acu-punch, Acuderm Inc., Ft. 
Lauderdale, FL), and subject to particulate analysis.   
2.2.5.2 Plasma reticulation 
 Plasma reticulation is a diffusive process where plasma reactive species rupture open 
and volatizes cell membranes at the surface of the foam51. As cell membranes at the surface 
are ruptured, the reactive species are able to access membranes further inside the foam matrix, 
allowing for reticulation of the entire foam sample51. Nine 100% TMHDI foam cylinders 8 
mm in diameter and 30 mm in length were cleaned using the protocol outlined in Section 2.4 
and then reticulated using a cold plasma treatment system (Aurora 0350 Plasma Surface 
Treatment System, Plasma Technology Systems, Belmont, CA). Power was set to 300 watts, 
gas flow rates were 800|200 for O2|CF4, and the cycle duration was 3 minutes
51. Once 
reticulated, the samples were subject to particulate analysis. 
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2.2.6. Cyclic inversion testing of particulate generation  
 
 
Figure 2.2: Schematic representation of the cyclic wash protocol used to evaluate uncleaned foam 
samples for particulate generation. 
 
Foam cylinders (n = 5) with 8 mm diameter and 3 cm length were cut from the twelve 
foam formulations (Table 2.1) using an 8 mm biopsy punch. Particulate data was collected for 
three distinct size ranges: >10 μm, >25 μm, and >50 μm, as recommended by the FDA. A 
procedure was developed for agitation of the foam samples in reference to USP 788. Briefly, 
foam sample agitation was achieved by successive inversion of a single foam cylinder 20 times 
in DI water. The resulting particulate levels in the DI water were measured using light 
obscuration (PC5000, Chemtrac Inc., Norcross, GA). Particle counts from the SMP foams were 
then compared to the limits for small volume infusions stated in USP 788 (Table 2.2) to 
characterize the foams on the basis of particulate generation. 
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Table 2.2: USP 788 Acceptable limits for injection or parenteral infusion37. 
Volume Particle Size Range Acceptable Number of Particles 
< 100 mL > 10 μm 6000 
< 100 mL > 25 μm 600 
 
As shown in Figure 2.2, each SMP foam cylinder was placed in a bottle containing 
100 mL DI water, agitated, removed from the water. This process constituted one inversion 
cycle. For cleaned foams, the suspension of particles was analyzed using the particle counter 
at this point. Uncleaned foam samples, however, were placed into a subsequent bottle of fresh 
DI water and subject to more inversion cycles. Each uncleaned sample was subjected to six 
inversion cycles or the number of cycles required to reach a plateau in the level of particulate 
generation (92 ± 3% decrease). Decreases in particulates from cycle to cycle were quantified 
using the following formula: 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝐷𝑒𝑐𝑟𝑒𝑎𝑠𝑒 =  
𝑁𝑛−1 − 𝑁𝑛
𝑁𝑛−1
 𝑥 100%  
where N is the number of particulates, and n is the cycle number. Due to the high sensitivity 
of the particle counter, baseline water counts were taken prior to each experiment to ensure 
that the DI water used met the criteria outlined in USP 788 (i.e., for water to be deemed 
particle-free, it must contain less than 1 particle > 10 μm in size per mL)37.  
2.2.7. Visual characterization 
 Visual characterization was performed to determine the geometries of particulates in 
all three ranges recorded (>10 µm, >25 µm, and >50 µm). Control foams (100% TMHDI, no 
filler), 1 wt% Al2O3 filler foams, 1 wt% SiO2 filler foams, 1 wt% W filler foams, and 3 vol% 
W filler foams were mechanically agitated to purposefully generate particulates. The 
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particulates were collected on an SEM mount containing carbon-tape and then placed under 
vacuum at 25° C for 48 hours. Then, the samples were sputter coated with a gold sputter coater 
(Cressington Sputter Coater, Ted Pella Inc., Redding, CA) for a duration of 60 seconds at a 
pressure of 20 mBar and imaged using a SEM (Neoscope JCM-5000, Jeol Inc., Peabody, MA). 
2.2.8. Cytocompatibility assay 
Control foams (100% TMHDI, no filler), 1 wt% Al2O3 filler foams, 1 wt% SiO2 filler 
foams, 1 wt% W filler foams, and 3 vol% W filler foams were subject to cyclic inversion with 
DI water according to the protocols outlined in Section 2.5. Forty mL of particulate solution 
was collected after the first and sixth cycles for each sample, and 40 mL of fresh DI water was 
collected as a control. P/S was added to each solution at 1% between collection and cell 
treatment to reduce contamination. The solutions were centrifuged for 10 min at 4400 rpm to 
pellet particulates; then, the supernatant was aspirated and exchanged for 2 mL of cell culture 
media to make 20x concentrated particulate solutions. Cell culture media was composed of 
DMEM, 10% NBCS, 1% P/S, and 0.1% fungizone.  
3T3 fibroblasts were seeded in 96-well tissue culture plates at a concentration of 5,000 
cells/well and incubated in a humidified incubator at 37°C with 5% carbon dioxide (CO2) for 
24 hours. Cell morphology was observed in all wells using a Nikon Eclipse TE 2000-S inverted 
microscope (Nikon, Melville, NY) and even cell distribution was confirmed before addition of 
the treatments. Cell culture media was aspirated from the wells, and 200 μL of the designated 
treatment solutions were added to each well. Cells were incubated with particulate treatments 
for 48 hours at 37°C with 5% CO2.  
Following incubation, cell morphology was observed in all wells using the Nikon 
inverted microscope to qualitatively evaluate changes induced by addition of the treatments. 
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The extract treatments were then removed and a NR uptake assay was utilized to quantify cell 
viability. NR is a red dye that is actively transported across the cell membrane where it 
accumulates within lysosomes52. After incubation with NR for 3 hours, the cells were fixed 
with a solution of 0.1% CaCl2 in 0.5% formaldehyde. The dye was solubilized in a solution of 
1% acetic acid in 50% ethanol for measurement. A plate reader (Tecan Infinite M200 Pro, 
Morrisville, NC) was used to measure the optical density at 540 nm to quantify the amount of 
remaining dye in each well. Cell viability is expressed as a percentage using the following 
equation: 
𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (𝑋) =
𝑂𝐷540(𝑋)
𝑂𝐷540(𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙)
 
where X is any treatment group and the negative control for cytocompatibility (DI water) is 
used as a standard that equals 100% viability. 
2.2.9. Statistical calculations 
Data was compiled and expressed as mean ± standard deviation (SD) (Table 3), and 
statistical analysis was performed using Student’s t-tests (Microsoft Excel, Microsoft, 
Redmond, Wash). The 12 foam compositions were divided into sub-groups and compared with 
other foams in their sub-group to determine statistical differences in particulate generation with 
a 95% confidence level (p < 0.05). The particulates >10 μm generated after the first wash were 
found to be most characteristic of the foam compositions. For this reason, first wash particulate 
levels were used when performing the t-tests.  
2.3. Results and discussion 
2.3.1.  Particle counter validation 
 Introduction of the calibrated microspheres into the particle counter returned that the 
particle counter used is capable of recording at least 75% of the particles introduced into the 
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system. Table 2.3 shows that the average particle levels over 8 runs was 11,493 ± 243 
signifying 76.6% recovery. These results validate the use of the Chemtrac particle counter as 
a device capable of accurately measuring particles in this size range.  
 
Table 2.3: Size and quantity of microspheres inputted, acceptable value for >75% recovery, and 
the average ± standard deviation of particle levels outputted by the particle counter. 
Input 
Microsphere 
Size (µm) 
Input Microsphere 
Number 
Output Size 
Range (µm) 
Chemtrac Output 
 (Acceptable Value) 
% 
Recovery 
15 15,000 10 – 25  
 
11,493 ± 243 
(11,250) 
76.6 
 
2.3.2. Analysis of uncleaned foams 
All uncleaned foam types generated the highest average number of particulates after 
the first inversion cycle, and the average number of particulates declined exponentially with 
each subsequent cycle. The magnitude of generated first-cycle particulates varied with foam 
composition, with the control foam generating the lowest number of particulates of the tested 
foam compositions. All of the foams tested exhibited a decrease in all three particulate size 
ranges after their initial cycle. On average, there was an 85 ± 6% decrease in particulates >10 
μm and >25 μm after the first cycle (Table 3). Subsequently, a 47 ± 14% decrease was observed 
between the second and third cycles. This trend was observed with all foam chemistries. 
Quantification of decreases in particulates observed after the first and second washes and 
average particulate counts for particles >10 μm and >25 μm are shown in Table 2.4. Particulate 
counts for particles >50 μm were very low (max of 0.17 particles per mL) and exhibited no 
discernable trends (Figure 2.7). The results from NR uptake assay supported the 
cytocompatibility of particulates generated from all tested foam compositions.  
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Table 2.4: Mean ± standard deviation of particulate numbers from the first cycle, and percent 
decrease after 1st and 2nd cyeles for particles > 10 μm and > 25 μm. 
Foam 
(N = 5) 
Mean 
Particulates 
>10 µm 
Mean 
Particulates 
>25 µm 
Mean % 
Decrease after 
1st cycle 
Mean % 
Decrease 
after 2nd cycle 
Control 760 ±140 70 ± 20 80 ± 10 50 ± 30 
50:50 1 wt% Al2O3 
1470 ± 550 
 
83 ± 40 70 ± 20 
30 ± 25 
 
20:80 1 wt% Al2O3 
2300 ± 520 
 
260 ± 330 90 ± 5 
50 ± 40 
 
0:100 1 wt% Al2O3 
1470 ± 860 
 
50 ± 20 70 ± 20 35 ± 30 
1 wt% SiO2 
1100 ± 240 
 
40 ± 20 80 ± 15 45 ± 30 
1 wt% W 
800 ± 220 
 
40 ± 10 90 ± 10 30 ± 20 
2 wt% W 
1070 ± 350 
 
60 ± 20 90 ± 5 50 ± 25 
3 wt% W 
1140 ± 550 
 
30 ± 10 75 ± 10 45 ± 30 
3 vol% W 1430 ± 460 130 ± 60 80 ± 10 50 ± 25 
5 vol% W 1380 ± 320 90 ± 40 90 ± 5 60 ± 10 
6 vol% W 1480 ± 440 130 ± 110 90 ± 5 55 ± 30 
8 vol% W 2080 ± 460 120 ± 100 85 ± 10 65 ± 30 
 
2.3.2.1. Effects of monomer ratio 
Particulate analysis of foams with varied monomer ratios of HDI to TMHDI (50:50, 
20:80, 0:100) revealed that foams containing a 20:80 HDI:TMHDI ratio (Figure 2.3) generated 
the highest number of particulates after their first inversion cycle. T-tests were performed to 
quantify differences in particulate generation in relation to monomer ratios. There was a 
statistically significant difference between the 20:80 HDI:TMHDI and the 50:50 HDI:TMHDI 
foams (p = 0.02) for >10 μm particle generation (Figure 2.3A). By increasing the ratio of 
TMHDI, the more hydrophobic of the two monomers, the foams become stiffer due to the 
reduced rate of water permeation into the foam matrix47. This increased stiffness could be the 
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cause of higher particulate levels in the foams with higher TMHDI ratios. There were no 
significant differences exhibited in the >25 μm size range (Figure 2.3B).  
 
 
Figure 2.3: Numbers of particulates (A) >10 μm and (B) >25 μm from 1 wt% Al2O3 foams with 
varying monomer ratios of 50:50 HDI:TMHDI, 20:80 HDI:TMHDI, and 100% TMHDI. n = 5; 
mean ± standard error displayed; *p < 0.05 relative to control; **p < 0.05 between the bracketed 
groups. USP 788 limit for particulates >10 µm = 6000; limit >25 μm = 600.  
 
2.3.2.2. Effects of filler type 
Variation in filler type resulted in differences in first cycle particulate generation 
(Figure 2.4). Of the three fillers, foams with W generated the lowest number of first cycle 
particulates and foams with Al2O3 produced the highest number of particulates. T-tests were 
performed to assess differences in particulate generation among the filler particles. Statistical 
analysis returned that the only significant difference (p < 0.05) was between the SiO2 foams 
and the W foams (p = 0.04) (Figure 2.4A). In general, adding fillers at low concentrations 
increased the small particulates (>10 μm) but reduced the larger (>25 μm) particulates. Filler 
incorporation reinforces the polymer matrix and, at low concentrations (0.5 – 1%), provides 
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physical net points that allow for improved resistance to mechanical deformation5. The SiO2 
foam most likely differed from the control foam because of the lower mass of the SiO2 
nanoparticles relative to the W and Al2O3 nanoparticles; due to this reduced mass, a higher 
number of SiO2 nanoparticles were required to achieve the same weight percent loading as the 
W and Al2O3 loaded foams
5. The increased numbers of >10 μm particulates (Figure 2.4A) 
seen in the filler foams relative to the control foam could be due to less stable areas of the foam 
with aggregates of filler nanoparticles, and the reduced numbers of >25 μm particulates 
(Figure 2.4B) could be related to the increased net points that the fillers provide.  
 
 
Figure 2.4: Numbers of particulates (A) >10 μm and (B) >25 μm from foams with W, SiO2, and 
Al2O3 filler types. n = 5; mean ± standard error displayed; *p < 0.05 relative to control; **p < 
0.05 between bracketed groups. USP 788 limit for particulates >10 µm = 6000; limit >25 μm = 
600.  
 
2.3.2.3. Effects of filler weight percent  
Variation in the weight percentage of W incorporated into the foam resulted in 
differences in particulate generation (Figure 2.5). Statistical analysis returned that the only 
significant difference (p < 0.05) was between the 2% W foams and the 3% W foams (p = 0.03) 
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in the >25 μm size range (Figure 2.5B).   The average magnitude of generated particulates >10 
μm recorded after the first inversion cycle generally increased as weight percentage W was 
increased (Figure 2.5A). However, T-tests returned that the number of generated particulates 
>10 μm did not differ significantly for the three weight percentages tested despite the observed 
positive correlation. The relatively low filler concentrations tested here were previously shown 
to have improved foam toughness and lowered particulate levels5. Thus, particulate levels that 
were generally less than or equal to the control foam was expected.   
 
 
Figure 2.5: Numbers of particulates (A) >10 μm and (B) >25 μm from foams with varying weight 
percentages of W. n = 5; mean ± standard error displayed. USP limit for particulates ≥10 µm = 
6000; limit >25 μm = 600. 
 
2.3.2.4. Effects of filler volume percent 
Variation in volume percentage of W incorporated into the foam also resulted in 
differences in first cycle particulate generation (Figure 2.6). T-tests showed that the 8 vol% 
W generated a statistically higher number of particulates than the 3, 5, and 6 vol% W foams (p 
< 0.05) in the smaller size range (Figure 2.6A). Despite the weak positive correlation 
demonstrated between increasing vol% and particulate levels (Figure 2.6A), none of the 3, 5, 
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or 6 vol% W foams differed significantly from one another. Increased filler concentrations (> 
4 vol%) were previously seen to lower material toughness48 and, as observed in this study, 
generated higher particulate levels in both the >10 μm and >25 μm size ranges (Figure 2.6A 
and 2.6B). High filler content decreases foam stiffness due to disruption of the foam matrix 
when filler aggregates replace the polymer within the foam struts and, ultimately, makes the 
foams more susceptible to brittle fracture48. 
 
 
Figure 2.6: Numbers of particulates (A) >10 μm and (B) >25 μm from foams with varying volume 
percentages of W. n = 5; mean ± standard error displayed; *p < 0.05 relative to control; **p < 
0.05 between bracketed groups. USP 788 limit for particulates >10 μm = 6000; limit >25 μm = 
600. 
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Figure 2.7: Particulates > 50 μm generated over 3 cyclic inversion cycles for all foam chemistries 
tested. n = 5; mean ± standard deviation displayed. No USP or FDA limit for particulates > 50 
μm. 
 
2.3.2.5. Visual characterization of foams 
Visual characterization of particulates from 1 wt% Al2O3, 1 wt% SiO2, 100% TMHDI, 
and 4 vol% W foams showed that the particulates were fragments of foam struts or foam-cell 
membranes. Figure 2.8 shows SEM images of various size particles generated from SMP foam 
cylinders. The average lengths and widths for the particles displayed in Figure 2.8 are (L x 
W): (A) 21 x 9 µm, (B) 53 x 40 µm, (C) 98 x 57 µm, and (D) 425 x 67 µm. Characterizing the 
shape allows us to better assess the embolic risk associated with the particles. Larger 
particulates (>50 µm) typically had length to width ratios greater than those seen in smaller 
particulates (<50 µm with length to width ratios approximately 1:1). Non-uniform particles 
produce greatest risk of invoking the inflammatory response and causing complication during 
embolization53.  
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Figure 2.8: SEM images of various sizes of particulates generated from the bulk SMP foam 
materials at (A) 10 µm, (B) 20 µm, (C) 50 µm, and (D) 100 µm scales.   
 
 
 
2.3.2.6. Cytocompatibility assay  
The results of the NR uptake assay are shown in Figure 2.9. No morphologic changes 
were observed after 48 hours of incubation with particulate solutions. Cell viability greater 
than 100% was observed for all treatment groups and ranged from 107% to 117%. This 
evidence supports the cytocompatibility of all particulate samples. Means compared using 
Student’s t-tests and no statistically significant differences were observed in viability between 
cycles 1 and 6 for any group.  
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Figure 2.9: Cell viability of 3T3 Fibroblasts determined by Neutral Red Uptake Assay. n = 5; 
mean ± standard error displayed. No significant differences were observed between the treatment 
groups.  
 
2.3.3. Particulate analysis of cleaned foams 
Quantification of particulate matter in cleaned foams is displayed in Figure 2.10. All 
of the foam chemistries tested exhibited particulate levels below the thresholds stated in USP 
788 for particles >10 µm (Figure 2.10A) and >25 µm (Figure 2.10B) (Limit >10 µm = 6000, 
limit >25 µm = 600). Cleaned foams exhibited significantly lower (p < 0.05) levels of 
particulates than the uncleaned foams. On average, cleaned foams exhibited particulate levels 
that were 55 ± 15% lower than those of the uncleaned foams.  
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Figure 2.10: Number of particulates (A) >10 µm and (B) >25 µm for 14 different compositions of 
cleaned SMP foams. USP 788 limit for particulates >10 μm = 6000; limit >25 μm = 600. 
 
2.3.4. Particulate analysis of reticulation methods 
Different reticulation modalities recorded differing levels of particulate matter in 100% 
TMHDI foams containing no filler particles (Figure 2.11). Both reticulation modalities 
generated statistically significantly higher (p < 0.05) levels of particulates >10 µm than those 
recorded in the control foams. Although mechanical reticulation generated higher levels of 
particulates than did plasma reticulation, the difference in particulate levels was not statistically 
significant. There were no statistical differences observed between the processes in the >25 
µm size range. 
Differences between the two reticulation modalities are likely due to a number of 
factors. First, the mechanical reticulation process involves much higher mechanical stresses 
and friction forces on the foam due to the nature of the process. Second, since the mechanical 
process requires physical perforation of the membranes using nitinol wires with higher 
mechanical properties than the foams being reticulated, there is more damage done to the foam 
matrix. Third, the 5-hour duration of the process entails that the foams are subject to these 
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higher mechanical stresses for a substantially longer period of time than the plasma processes. 
With plasma reticulation, enough energy is generated within the plasma chamber to cause a 
controlled burning of the foam membranes. This means that the foam struts are subject to 
minimal mechanical forces during the brief 3-minute process. The difference between the 
plasma reticulated foams and the control foams is most likely due to the fact that, although the 
plasma reticulated foams are subject to minimal mechanical forces, the controlled burning of 
the membranes causes a marginal decrease in foam strut diameter. This decrease in diameter 
lowers the mechanical strength of the foam and increases the risk of micro-fracture within the 
foam matrix.   
 
 
Figure 2.11: Particulates generated by mechanical and plasma reticulation. 100% TMHDI 
foam was used as a control and DI water particulate levels are recorded. n = 9; mean ± 
standard error displayed; *p < 0.05 relative to control. 
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2.4. Conclusions 
The overarching goal of this study was to evaluate SMP foams as a candidate for a 
component of an NED on the basis of particulate generation. The results from this benchtop 
study indicate that particulates in the two ranges addressed by USP 788 (>10 μm and >25 μm) 
are below the stated limits. While these limits do not directly address medical devices, they 
allow us to compare our materials to the most relevant standard. The third size range (>50 μm) 
tested here does not have a limit defined by either the USP or FDA, but the level of particulates 
recorded in these experiments were very low for this size range. The results from the NR assay 
support the cytocompatibility of particulates generated from the SMP foams. Analysis of the 
reticulation modalities returned that plasma reticulation generates lower levels of particulates 
than mechanical reticulation. Furthermore, the cleaning protocol currently in place 
successfully lowers the particulate levels of the foams. 
None of the three fillers resulted in particulate levels that would eliminate them as 
candidates for the device. The trends displayed in this study indicated that when varying weight 
and volume percentage W in the foams, a large increase (> 3%) in weight or volume percentage 
is required to produce significant increases in particulate levels.  
Moving forward, there are some important considerations that need to be made. When 
selecting a foam composition for the neurovascular embolization device, it is important to 
consider that multiple foam devices are often deployed into the aneurysm sac during each 
procedure. Also, the volume of foam used in an embolization device will be substantially lower 
than the volume tested and must be evaluated separately on the basis of particulates. Further 
analysis will need to be performed to evaluate particulate generation after processing and 
during delivery on the benchtop.  
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CHAPTER III 
QUANTIFICATION OF PARTICULATES GENERATED DURING DEVICE DELIVERY 
INTO BENCHTOP FLOW SYSTEMS 
 
3.1 Introduction 
After quantifying and characterizing the particulate levels of various SMP foams in 
Chapter II, the next step was to evaluate the device upon delivery into benchtop flow models 
that simulate a clinical embolization procedure. In a guidance document for a Class II medical 
device, the FDA recommends reporting the total quantity and size of particulates generated 
during simulated device use in three distinct size ranges (>10 μm, >25 μm, and >50 μm) to 
comprehensively report on any sub-visible particulate matter present38. 
The NED includes a pusher wire, attachment junction, and the foam-over-coil (FOC) 
implant. The assembly was subject to particulate analysis during acute application to remain 
in compliance with FDA recommendations29. Devices were delivered via microcatheter into a 
straight tube and a tortuous pathway model containing heated DI water. These experiments 
provided in vitro feedback on the amount of particulate matter that is generated during device 
delivery. The method and results for device fabrication, delivery, and particulate analysis are 
reported in this chapter.  
3.2. Methods 
3.2.1. Device fabrication 
The device consists of SMP foam on a platinum wound nitinol backbone wire. HPED 
(99%), TEA (98%), TMHDI, and DI water are used to synthesize SMP foams using the three 
step method reported in Chapter II. Raw SMP foam is cleaned with a series of IPA and RO 
water sonications and tumbles, and then used in the assembly of neurovascular embolization 
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devices. The platinum wound nitinol wire was annealed over a mandrel in a furnace to give a 
helical shape, quenched in RO water, and cleaned using IPA and RO water10. SMP foam 
cylinders were cut using a 1 mm diameter biopsy punch. The nitinol wire was threaded axially 
through the SMP foam, and radially compressed using a heated stent crimper; the compressed 
SMP foam was secured to the nitinol wire using UV-cure epoxy (Figure 3.1)10. The completed 
device was laser welded to a guidewire to enable delivery via microcatheter during testing. 
 
 
Figure 3.1: Fully assembled foam embolization device containing SMP foam crimped over 
platinum wound nitinol backbone wire. Helical diameter = 6 mm; foam length = 10 cm. 
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3.2.2.  Delivery into a straight tube 
 
 
Figure 3.2: Schematic representation of the flow system to deliver devices into a straight tube. 
The red path denotes the microcatheter and the red box is the delivery zone. Device is inserted 
through hemostasis valve A. 
 
 
 
Each experimental run consisted of delivery of one FOC implant via micro-catheter 
into a straight ¼” inner diameter tube (Figure 3.2) as DI water was pulled from a heated 
container via a peristaltic pump. The DI water was heated to an outlet temperature of 37° C, 
and pumps were adjusted to produce a flow rate of 100 ± 5 mL/min. A syringe pump was set 
to 0.4 mL/min to provide a constant flow of water within the microcatheter. Prior to device 
insertion, water from the flow system was collected from the outlet for 5 minutes to record the 
baseline particulate level of the flow system. Then, the device was inserted through hemostasis 
valve A (Figure 3.2) and manually advanced through the microcatheter until 1-3 mm of device 
was exposed at the distal tip of the microcatheter. Devices were cyclically advanced and 
retracted for 5 minutes using an Insight 30 Material Tester (MTS Systems Corporation, Eden 
Prairie, MN) or until stop criteria are observed. Stop criteria are denoted by (1) foam shearing, 
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(2) FOC to pusher detachment, (3) pusher buckling greater than 3 cm from the pushing plane, 
and/or (4) load exceeding 1.5 N absolute value (Figure 3.3). Table 3.1 contains detailed 
descriptions for each stop criterion. Particulate collection began concurrently with device 
insertion through hemostasis valve A into the inner lumen of the microcatheter.   
 
 
Table 3.1: Detailed descriptions of stop criteria for device delivery testing. 
Stop Criteria Description Figure 
Foam shearing 
Foam delaminates from the 
coil, typically during retraction 
into the microcatheter, and 
fractures. 
3.3A 
FOC to pusher detachment 
FOC stops moving with the 
pusher wire while pusher 
continues to push/pull through 
microcatheter 
3.3B 
Pusher buckling 
Pusher buckles > 3 cm from the 
straight path at the proximal 
end out of the microcatheter 
without visible movement at the 
distal end 
3.3C 
Load exceeds 1.5 N 
Real-time load measurement 
exceeds 1.5 N absolute value 
--- 
 
 
 
Figure 3.3: Stop criteria for the cyclic retraction testing of the embolization device. (A) Foam 
shearing, (B) FOC to pusher detachment, and (C) pusher buckling. 
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3.2.3. Delivery into a tortuous model 
 
 
 
 
Figure 3.4: (A) Schematic representation of the flow system to deliver devices into a tortuous 
model. The red path denotes the microcatheter and the red box is the delivery zone. Device is 
inserted through hemostasis valve A. (B) Tortuous model used during testing. Microcatheter 
pathway is highlighted and a zoomed view of the device at the distal tip of the catheter is shown; 
scale is mm. 
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Each experimental run consisted of delivery of one FOC implant into a tortuous model 
via micro-catheter (Figure 3.4B) as DI water was pulled from a heated container via a 
peristaltic pump. The DI water was heated to an outlet temperature of 37° C, and pumps were 
adjusted to produce a flow rate of 31 ± 3 mL/min to simulate physiologic flow in a typical 
cranial artery54. A syringe pump was set to 0.4 mL/min to provide a constant flow of water 
within the microcatheter. Prior to device insertion, water from the flow system was collected 
from the outlet for 5 minutes to record the baseline particulate level of the flow system. Then, 
the device was inserted through hemostasis valve A (Figure 3.4A) and manually advanced 
through the microcatheter until 1-3 mm of device was exposed at the distal tip of the 
microcatheter (Figure 3.4B). Devices were cyclically advanced and retracted for 5 minutes 
using an Insight 30 Material Tester (MTS Systems Corporation, Eden Prairie, MN) or until 
stop criteria (Figure 3.3 and Table 3.1) were observed. Particulate collection began 
concurrently with device insertion through hemostasis valve A into the inner lumen of the 
microcatheter. One collection bottle was used for the entire 5-minute duration of the test.  
3.2.4. Particulate analysis 
In both the straight tube and tortuous model tests, each device produced two bottles 
containing particulate suspensions; one bottle contained the baseline particulates and the other 
contained the particulates generated during cyclic advancement and retraction of the device. 
The bottles were sonicated for one minute to re-suspend the particulates, and then analyzed 
using the particle counter.  
3.3. Results and discussion 
Device delivery into both a straight tube and tortuous model returned particulate levels 
that were below the thresholds stated in USP 788. The data was normalized by subtracting the 
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baseline particulate levels from the device levels. Figure 3.5A depicts the average particle 
levels recorded by the entire devices delivered into a straight tube. Figure 3.5B depicts the 
quantity of particulates per cm of device delivered. Figure 3.6A and 3.6B depict the average 
particulate levels for the device and per cm of device for embolization devices delivered into 
a tortuous model. In a clinical setting, the number of embolization devices that are implanted 
is dependent upon a number of different factors, including aneurysm size, FOC implant length, 
and physician satisfaction that the aneurysm is fully occluded30.  
 Differences between the particulate levels in the straight tube delivery and the tortuous 
delivery are likely due to a number of inconsistencies between the two flow setups. Primarily, 
the length of tubing used in the tortuous path testing was substantially shorter than the straight 
tube testing causing the baseline particle levels to be lower in the tortuous flow model. 
Secondly, the flow rate used during straight tube delivery was approximately three times higher 
than the flow rate used in the tortuous testing. The change in flow rates was due to findings 
from a literature review that identified physiologic flow rates for vasculature in the cranial 
region where most clinical neurovascular embolization procedures are performed. In addition, 
the majority of device fabrication and benchtop testing for both tests was not performed in a 
clean room or laminar flow hood. Thus, the levels of environmental particulates present during 
processing and delivery were markedly higher than those expected from a final device that 
would be used in a clinical setting. 
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Figure 3.5: (A) Particulates recorded from delivery of a single embolization device into a straight 
tube in 3 size ranges. (B) Particulates per cm of device delivered in 3 different size ranges (n = 3). 
 
 
 
 
 
 
 
Figure 3.6: (A) Particulates recorded from delivery of a single embolization device into a tortuous 
pathway model in 3 size ranges. (B) Particulates per cm of device delivered in 3 different size 
ranges (n = 5). 
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3.4. Conclusions 
 Analysis of the embolization devices during delivery showed that the particulate levels 
are below the limits stated in the most relevant standard. Building on the results from Chapter 
II, this chapter further supports the use of SMP foam-based devices as promising candidates 
for embolization of cranial aneurysms. A definitive comparison between the straight tube 
testing and the tortuous pathway testing cannot be made because there was variability in test 
parameters such as flow rate and tubing length. The straight tube testing served as feasibility 
testing for the more rigorous tortuous pathway testing.  
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CHAPTER IV 
CONCLUSIONS AND FUTURE WORK 
 
4.1 Summary  
 SMP foams are promising candidates for endovascular occlusion applications because 
of their high volume recovery and ability to passively actuate at body temperature. The embolic 
risk posed by these devices is unknown and unreported. This thesis evaluated SMP foams and 
foam-based devices particulate generations. The FDA requires that particulate matter during 
processing, sterilization and delivery of medical devices be reported, but no prior work had 
been done to characterize particulate matter in these SMP foams. Initial protocols relied 
heavily on those outlined in USP 788, the standard for particulate matter in parenteral 
injections. The ability to quantify particulate levels enables mitigation of embolic risk posed 
by the foam-based embolization devices.  
 In Chapter II, bulk material analysis reflected that particle levels are in compliance with 
the particle limits defined in USP 788. Evaluation of the current cleaning protocol showed that 
it effectively reduces particulate levels. The particles and chemicals remaining within the foam 
matrix are driven out by the successive sonication and tumble cycles during cleaning. Thus, 
when analyzed post-cleaning, there are less loose foam struts and environmental particles 
within the foam that are generated by the agitation portion of the particulate quantification 
protocol. Reticulation of the foams was originally a cause for concern because it was 
hypothesized that the high friction involved in the mechanical reticulation process could 
generate unacceptable levels of particulates. This hypothesis was rejected upon particulate 
evaluation of the reticulation processes. While mechanical reticulation did produce the highest 
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particulate levels, they remained below the limits outlined in USP 788. Moving forward, 
neither plasma nor mechanical reticulation will drastically increase the levels of particulates 
generated by the foams. Overall, the best approach to mitigating particulate generation in bulk 
SMP materials is to minimize any mechanical forces that the foam is subject to in its glassy 
state (< Tg).  Administering concentrated particulate treatments to fibroblasts showed that even 
a concentrated dose of particulates generated by a typical agitation cycle had a minimal effect 
on cell viability and supported the cytocompatibility of the SMP foams. In conclusion, bulk 
foams did not generate alarming levels of particulates. 
 Particulate analysis during device delivery built on the results from the bulk material 
testing by assessing the device in a clinically relevant benchtop flow system. Once inserted 
into the flow system, the device was cyclically maneuvered in and out of the microcatheter to 
simulate the worst-case scenario for device manipulation. Testing in worst-case scenarios helps 
to minimize performance related issues in the future. Testing returned that the devices 
generated particles at levels well below the USP standard. The results suggest that the device 
particle levels will remain below the USP limits even if multiple devices are implanted. This 
result is important, because clinical procedures typically involve the implantation of multiple 
embolic devices per aneurysm.  
4.2 Challenges and future work 
 During the development of a protocol for quantifying particulates in SMP foams, LO 
was selected as the method of particle analysis using a suction based particle counter. Although 
the device is cost efficient and easy to use, there are several limitations. Specifically, suction 
fed devices require the user to leave a small exclusion volume that cannot be analyzed. While 
the excluded volume only accounts for a small percentage of the total sample volume, it may 
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alter the results. An alternative approach that addresses this issue is a gravity-fed particle 
counter. These devices allow for analysis of the entire sample volume so that results are 
representative of the whole sample. This method is desirable when working to quantify the 
whole sample volume.  
 In addition, further validation of the particle counter will be performed to ensure that 
the system is functioning as intended when recording larger particles. Validation will be 
performed by introducing a known quantity of particles 70 µm in diameter into the device and 
ensuring that at least 75% of the particles are recorded by the device. This will supplement the 
validation that was performed in Chapter III using 15 µm diameter microspheres. Upon 
purchase of the device, it was validated by the manufacturer, but providing in-house validation 
will be cost-effective and time efficient.  
 Similarly, the particle counter is limited in its ability to quantify particles larger than 
200 µm. Larger particles pose a significantly higher risk of embolization. If introduced into 
blood circulation, a small number of these large particles could result in serious complications 
post-embolization. A future direction involves adding an additional step to the particulate 
quantification protocol. The particle suspension solution will first be filtered through a 200 µm 
filter, then the larger particles will be counted using a microscopy technique outlined in USP 
788. Since the larger particles are visible under minimal magnification, quantification can be 
carried out in minimal time using a simple light microscope.  
 Upon evaluation of the flow setup for evaluating particulates generated during device 
delivery, some limitations were identified. First, the devices are delivered into a mock vessel 
with fluid continuously flowing past the device. In a clinical environment, the device is 
deployed into an aneurysm sac that is subject to reduced fluid velocities and differing flow 
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patterns. A future direction for delivery testing is to deliver the devices into a mock aneurysm 
model while flowing heated water past the aneurysm and collecting the water at the outlet for 
particulate analysis. This model will provide a more realistic simulation of flow parameters in 
the clinical procedure. Second, the tortuous model used does not simulate a worst-case scenario 
for cerebral tortuosity. A future direction involves increasing the tortuosity of the pathway that 
the microcatheter and device take to arrive at the delivery site. This method will provide a 
better idea of how the device will perform in difficult procedures, and limit future 
complications.  
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APPENDIX 
 
 
Validation and verification of LO particle counter 
Validation and verification are important processes that confirm that a system is 
performing as intended. Validation shows, through objective evidence, that a system will 
perform as intended. Similarly, verification shows, through objective evidence, that system 
requirements have been fulfilled. Validation of the LO particle counter was performed by 
introducing a known quantity of particles of a known size into the device and ensuring that at 
least 75% are recovered. The accuracy of the particle counter used throughout these studies 
was verified using an alternative method for particulate quantification.  
Method 
Microscopy evaluation is provided in USP 788 as an alternate approach to LO when 
quantifying particles in solution. The same inversion protocol as outlined in Chapter II, Section 
2.5 was followed to generate particles from the sample. Then, the sample solution was filtered 
through a 10 µm – pore filter assembly and examined with a binocular microscope. The filter 
was placed over a 5 cm x 5 cm grid and manually counted on a binocular light microscope 
(Leica MZ 16, Meyer Instruments, Houston, TX). LO counts were performed to compare 
against the microscopy counts. 100% TMHDI foams synthesized using the steps outlined in 
Chapter II, Section 2.2. Phloxine, a red dye making the foam bright pink, was incorporated 
during synthesis to maximize visibility under the microscope.  
Results and discussion 
Particulate analysis using both LO and microscopy on foams with identical compositions 
returned that the microscopy technique performed was unable to detect particles ranging from 
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10 – 25 µm. Figure A-1A displays particle levels in the phloxine foams in three size ranges. 
Figure A-1B displays only one size range for the microscopy technique because only one filter 
(10 µm pores) was used in the assembly. This result shows that the particle levels recorded by 
the microscopy technique are correspondent with counts for particles >25 µm for the LO 
particle counter. There are a number of reasons why this could have happened. First, the 
microscope resolution was limited to approximately 25 µm, making it very difficult to discern 
small particles (10 – 25 µm). Second, particle aggregates were difficult to quantify under 
microscope. Lastly, microscopy counts were performed by counting the number of particles 
trapped in the 10 µm – pore filter. This approach made it difficult to see any smaller particles 
trapped in the body of the filter (filter thickness = 300 µm). In comparison, LO is a faster, more 
repeatable process with higher resolution. Validation of the LO particle counter, however, is a 
necessary step to ensure that the device is functioning as specified in the requirements.  
 
 
Figure A-1: Two particle quantification techniques: (A) LO and (B) microscopy; n = 3.  
 
